PN summer web series kicks off in July! Learn more

KRN5500 Demonstrated Significant Decrease in the Intensity of Neuropathic Pain in Patients with Cancer

DARA BioSciences, recently awarded fast track designation from the FDA for the development of their new drug for the treatment of neuropathic pain, has just released the results of a Phase II safety and efficacy study. The study showed KRN5500 demonstrated a statistically significant improvement in the relief of neuropathic pain versus a placebo.  READ MORE

Source: Newswise